FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126189372> ?p ?o ?g. }

• W2126189372 abstract "Abstract Background Clinical profiling of two components for a synthetic peptide-based virosomal malaria vaccine has yielded promising results, encouraging the search for additional components for inclusion in a final multi-valent vaccine formulation. This report describes the immunological characterization of linear and cyclized synthetic peptides comprising amino acids 211-237 of Plasmodium falciparum merozoite surface protein (MSP-3). Methods These peptides were coupled to phosphatidylethanolamine (PE); the conjugates were intercalated into immunopotentiating reconstituted influenza virosomes (IRIVs) and then used for immunizations in mice to evaluate their capacity to elicit P. falciparum cross-reactive antibodies. Results While all MSP-3-derived peptides were able to elicit parasite-binding antibodies, stabilization of turn structures by cyclization had no immune-enhancing effect. Therefore, further pre-clinical profiling was focused on FB-12, a PE conjugate of the linear peptide. Consistent with the immunological results obtained in mice, all FB-12 immunized rabbits tested seroconverted and consistently elicited antibodies that interacted with blood stage parasites. It was observed that a dose of 50 μg was superior to a dose of 10 μg and that influenza pre-existing immunity improved the immunogenicity of FB-12 in rabbits. FB-12 production was successfully up-scaled and the immunogenicity of a vaccine formulation, produced according to the rules of Good Manufacturing Practice (GMP), was tested in mice and rabbits. All animals tested developed parasite-binding antibodies. Comparison of ELISA and IFA titers as well as the characterization of a panel of anti-FB-12 monoclonal antibodies indicated that at least the majority of antibodies specific for the virosomally formulated synthetic peptide were parasite cross-reactive. Conclusion These results reconfirm the suitability of IRIVs as a carrier/adjuvant system for the induction of strong humoral immune responses against a wide range of synthetic peptide antigens. The virosomal formulation of the FB-12 peptidomimetic is suitable for use in humans and represents a candidate component for a virosomal multi-valent malaria subunit vaccine." @default.
• W2126189372 created "2016-06-24" @default.
• W2126189372 creator A5003339715 @default.
• W2126189372 creator A5011479792 @default.
• W2126189372 creator A5026314935 @default.
• W2126189372 creator A5029640432 @default.
• W2126189372 creator A5030049038 @default.
• W2126189372 creator A5031161954 @default.
• W2126189372 creator A5057390212 @default.
• W2126189372 creator A5089382312 @default.
• W2126189372 creator A5091175877 @default.
• W2126189372 date "2009-12-01" @default.
• W2126189372 modified "2023-10-13" @default.
• W2126189372 title "Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine" @default.
• W2126189372 cites W1538106821 @default.
• W2126189372 cites W1586351831 @default.
• W2126189372 cites W1661961827 @default.
• W2126189372 cites W190349426 @default.
• W2126189372 cites W1978059116 @default.
• W2126189372 cites W1981254056 @default.
• W2126189372 cites W1985158166 @default.
• W2126189372 cites W1985243017 @default.
• W2126189372 cites W1997659370 @default.
• W2126189372 cites W2008629172 @default.
• W2126189372 cites W2018969381 @default.
• W2126189372 cites W2019057969 @default.
• W2126189372 cites W2025587796 @default.
• W2126189372 cites W2028506549 @default.
• W2126189372 cites W2030654414 @default.
• W2126189372 cites W2051809585 @default.
• W2126189372 cites W2060979783 @default.
• W2126189372 cites W2061516190 @default.
• W2126189372 cites W2067559517 @default.
• W2126189372 cites W2070345715 @default.
• W2126189372 cites W2074238243 @default.
• W2126189372 cites W2097352048 @default.
• W2126189372 cites W2110157529 @default.
• W2126189372 cites W2128229836 @default.
• W2126189372 cites W2129193946 @default.
• W2126189372 cites W2132466777 @default.
• W2126189372 cites W2144996971 @default.
• W2126189372 cites W2145303222 @default.
• W2126189372 cites W2155827721 @default.
• W2126189372 cites W2164128190 @default.
• W2126189372 cites W2166262629 @default.
• W2126189372 doi "https://doi.org/10.1186/1475-2875-8-314" @default.
• W2126189372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2805693" @default.
• W2126189372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20042100" @default.
• W2126189372 hasPublicationYear "2009" @default.
• W2126189372 type Work @default.
• W2126189372 sameAs 2126189372 @default.
• W2126189372 citedByCount "8" @default.
• W2126189372 countsByYear W21261893722012 @default.
• W2126189372 countsByYear W21261893722016 @default.
• W2126189372 countsByYear W21261893722020 @default.
• W2126189372 crossrefType "journal-article" @default.
• W2126189372 hasAuthorship W2126189372A5003339715 @default.
• W2126189372 hasAuthorship W2126189372A5011479792 @default.
• W2126189372 hasAuthorship W2126189372A5026314935 @default.
• W2126189372 hasAuthorship W2126189372A5029640432 @default.
• W2126189372 hasAuthorship W2126189372A5030049038 @default.
• W2126189372 hasAuthorship W2126189372A5031161954 @default.
• W2126189372 hasAuthorship W2126189372A5057390212 @default.
• W2126189372 hasAuthorship W2126189372A5089382312 @default.
• W2126189372 hasAuthorship W2126189372A5091175877 @default.
• W2126189372 hasBestOaLocation W21261893721 @default.
• W2126189372 hasConcept C147483822 @default.
• W2126189372 hasConcept C159047783 @default.
• W2126189372 hasConcept C159654299 @default.
• W2126189372 hasConcept C195616568 @default.
• W2126189372 hasConcept C203014093 @default.
• W2126189372 hasConcept C22889606 @default.
• W2126189372 hasConcept C2776789287 @default.
• W2126189372 hasConcept C2778048844 @default.
• W2126189372 hasConcept C2778371730 @default.
• W2126189372 hasConcept C2780868878 @default.
• W2126189372 hasConcept C2781034427 @default.
• W2126189372 hasConcept C32611913 @default.
• W2126189372 hasConcept C542903549 @default.
• W2126189372 hasConcept C71924100 @default.
• W2126189372 hasConcept C86803240 @default.
• W2126189372 hasConcept C8891405 @default.
• W2126189372 hasConceptScore W2126189372C147483822 @default.
• W2126189372 hasConceptScore W2126189372C159047783 @default.
• W2126189372 hasConceptScore W2126189372C159654299 @default.
• W2126189372 hasConceptScore W2126189372C195616568 @default.
• W2126189372 hasConceptScore W2126189372C203014093 @default.
• W2126189372 hasConceptScore W2126189372C22889606 @default.
• W2126189372 hasConceptScore W2126189372C2776789287 @default.
• W2126189372 hasConceptScore W2126189372C2778048844 @default.
• W2126189372 hasConceptScore W2126189372C2778371730 @default.
• W2126189372 hasConceptScore W2126189372C2780868878 @default.
• W2126189372 hasConceptScore W2126189372C2781034427 @default.
• W2126189372 hasConceptScore W2126189372C32611913 @default.
• W2126189372 hasConceptScore W2126189372C542903549 @default.
• W2126189372 hasConceptScore W2126189372C71924100 @default.
• W2126189372 hasConceptScore W2126189372C86803240 @default.
• W2126189372 hasConceptScore W2126189372C8891405 @default.
• W2126189372 hasIssue "1" @default.
• W2126189372 hasLocation W21261893721 @default.

• next